Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells

Prostate

Volumn 66, Issue 11, 2006, Pages 1194-1202

  Sutton, M Tandy ^a   Yingling, Melissa ^a   Vyas, Ash ^a   Atiemo, Humphrey ^b   Borkowski, Andrew ^c   Jacobs, Stephen C ^b   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Apoptosis; Cell adhesion; Finasteride; Prostate cells; Vascularity

Indexed keywords

ANGIOGENESIS INHIBITOR; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BENIGN TUMOR; CELL ADHESION; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; MICROVASCULATURE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM;

APOPTOSIS; CELL ADHESION; CELLS, CULTURED; FACTOR VIII; FINASTERIDE; HUMANS; IN SITU NICK-END LABELING; MALE; MICROCIRCULATION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR CELLS, CULTURED;

EID: 33746795081     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20444     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Isaacs JT. The biology of hormone refractory prostate cancer: Why does it develop? Urol Clin North America 1999;26:263-273.
3. Bare RL, Torti FM. Endocrine therapy of prostate cancer. Cancer Treat Res 1998;94:69-87
4. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: It is not only the cancer cell's fault. Endocr Relat Cancer Rev 2002;9:61-73.
5. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989;2:33-50.
6. Bruckheimer EM, Kyprianou N. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res 2000;301:153-162.
7. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122:552-562.
8. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. The Prostate 2000;42:150-160.
9. Rittmaster RS, Stoner E, Thompson DL. Effect of MK-906, a specific 5%-reductase inhibitor on serum androgens and androgen conjugates in normal men. J Androl 1989;10:259-262.
10. The Finasteride Study Group. Finastehde (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
11. McConnell JD, Bruskesvitz R, Walsh PC, Andriole G, Lieber M, Holtgresv HL, Rochrbom CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. for the finastcride long-term efficacy and safety study group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among with benign prostatic hyperplasia. New Engl J Med 1998;338:557-563.
12. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGingley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
13. Vaughan D, Imperato-McGinley J, McConnell J, Matsumoto AM, Bracken B, Roy J, Sullivan M., Pappas F, Cook T, Daurio C, Meehan A, Stoner E, Waldstreicher J. Long-term (7- to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002;60:1040-1044.
14. Walsh PC, Madden JD, Harrod MJ. Familial incomplete male pseudohermaphroditism, type 2: Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974;291:944-949.
15. Boyle P, Could AL, Roehrbom CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Metaanalysis of randomized clinical trials. Urology 1996;48:398-405.
16. Kaplan SA, Holtgrewe HL, Bruskesvitz R, Saltzman B, Mobley D, Narayan P, Lund RH, Weiner S, Wells G, Cook TJ, Meehan A, Waldstreicher J. For the proscar long-term efficacy and safety study group. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 2001;57:1073-1077.
17. Hochberg DA, Basilote JB, Armenakas NA, Vasovic L, Sehevehuk M, Pareeek G, Fracchia JA. Decreased suburethral prostatic micro vessel density in finasteride treated prostates: A possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002;167:1731-1733.
18. Kearney MC, Bingham JB, Bergland R, Meade-D'Alisera P, Puchner PJ. Clinical predictions in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 2002;167:2489-2491.
19. Perimenis P, Gyftopoulos K, Markou S, Barbalias G. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: A prospective, randomized, controlled study. Urology 2002;59:373-377.
20. Lobaccaro JM, Boudon C, Lechevallier E, Mottet N, Rebillard X, Lumbroso S, Gibelin S, Sultan C. Effect of finasteride on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates. Cell Mol Biol 1996;42:511-518.
21. Buttyan R, Ghafar MA, Shabsigh A. The effects of androgen deprivation on the prostate gland: Cell death mediated by vascular regression. Cur Opin Urol 2000;10:415-421.
22. Ruoslathi E, Reed JC. 1994. Anchorage dependence, integrins and apoptosis. Cell 1994;77:477-478
23. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993;4:953-961.
24. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626.
25. Glassman DT, Chon JK, Brockowski A, Jacobs SC, Kyprianou N. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-β expression in benign prostatic hyperplasia. The Prostate 2001;46:45-51.
26. Keledjian K, Kim G, Borkowski A, Isaacs JT, Jacobs SC, Kyprianou N. Suppression of human prostate tumor vascularity by the α1-adrenoceptor antagonist, terazosin. The Prostate 2001;48:71-78.
27. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001;61:8135-8142.
28. Bruckheimer EM, Kyprianou N. Dihydrotestosterone enhances transforming growth factor-β-induced apoptosis in hormone-sensitive prostate cancer cells. Endocrinology 2001;142:2419-2426.
29. Kyprianou N. Doxazosin and terazosin suppress prostatic growth by inducing apoptosis. J Urol 2003;169:1520-1529.
30. Moon SY, Moon WC, Hak RC. Finasteride inhibits angiogenesis and expression of VEGF in human BPH. J Urol 1998;159:332 (abstract #1276).
31. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg D, Basillote JB, Fracchia JA. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003;169:20-23.
32. Marks LS, Partin AW, Dorey FJ. Long-term effects of finasteride on prostate tissue composition. Urology 1999;53:574-580.
33. Kirby RS, Roehrborn CG, Boyle P. For the PREDICT Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003;61:119-126.
34. Jain RK, Safabaksh N, Sckell A, Chen Y, Jiang P, Benjiamin L, Yuan F, Keshet E. Endothelial cell death, angiogenesis and microvascular function of castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998;95:10820-10825.
35. Homma Y, Kaneko M, Kondo Y, Kawabe K, Kakizoe T. Inhibition of rat prostate carcinogenesis by a 5 alpha-reductase inhibitor, FK143. J Natl Cancer Inst 1997;89:803-806.
36. Zhu Z, Sanchez-Sweatman O, Huang X. Anoikis and metastastatic potential of cloudman 591 melanoma cells. Cancer Res 2001;61:1707-1716.
37. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the reactive tumor microenvironment: Significance in prostate cancer metastasis. Cancer Res 2005;63:11230-11235.
38. Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F, Haillot O. Effect of nonsteroidal antiinflammatory agents and finasteride on prostate cancer risk. J Urol 2002;168:1985-1988.
39. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:213-222.
40. Lee Y-F, Lin W-J, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the anti-androgen hydroxyflutamide in androgen-receptor-negative prostate cancer cells. Cancer Res 2002;62:6039-6044.